Pharmaceuticals

• • Pipeline Code
  • Estimated Initial indication
  • Originator
• Pre-
  clinical
• Clinical Study
  Phase 1
• Clinical Study
  Phase 2
• Clinical Study
  Phase 3
• NDA
• Approval
• Launch
• Partner

• SP-01

  Chemotherapy Induced Nausea and Vomiting

  ProStrakan(Kyowa Kirin)
  overview
• China (Beijing, Shanghai, Guangzhou : own sales area)
  Taiwan, Hong Kong etc. (Kyowa Kirin : Sublicensee)

• Lee’s Pharma：

  China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau

  Kyowa Kirin：

  Taiwan, Hong Kong etc.

• SP-02

  Peripheral T-Cell Lymphoma

  ZIOPHARM Oncology, Inc
  overview
• Japan, Korea, Taiwan, HK (Pivotal PII study completion: Achieved primary endpoint, preparation for NDA filing)
  China　（Phase II/III, pivotal study preparation）
  US　(Phase IIA, completion）
  EU　(Pre-clinical, completion)

• Meiji Seika Pharma：

  Japan

  HB Human BioScience SAS：

  Latin America

• SP-04

  Chemotherapy Induced Peripheral Neuropathy (CIPN)

  Egetis Therapeutics AB
  overview
• Japan, South Korea, Taiwan, HK (Phase III, Completion)
  China
  US and EU (Phase III, Completion by Egetis)

• Maruho Co., Ltd.：

  Japan

• SP-05

  Increase efficacy of fluorouracil

  Isofol Medical AB
  overview
• Japan（Global Phase III）
  US, Canada, EU, Australia（Global Phase III by Isofol）

Medical Device

• • Pipeline Code
  • Estimated Initial indication
  • Originator
• Pre-clinical
• Clinical Study
• NMDA
• Approval
• Launch
• Partner

• SP-03

  Pain associated oral mucositis

  Camurus AB
  overview
• Japan
  China (Beijing, Shanghai, Guangzhou : own sales area)
  South Korea

• Meiji Seika Pharma：

  Japan

  Lee’s Pharma：

  China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan

  Synex：

  South Korea

New Drug Candidates

• Nucleic acid drug candidate for peritoneal metastases (disseminated metastases developing in the peritoneum): Option agreement for in-license of worldwide rights with GeneCare Research Institute Co., Ltd.
• New drug candidates for rare disease and/or oncology based on RNA editing technology utilizing pentatricopeptide repeat (PPR) protein platform technology: Joint R&D agreement with EditForce Inc.